TrialThe Journal of infectious diseases2025

Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.

Lucía Bailón et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.